Journal of Clinical Pharmacy and Therapeutics

Cover image for Vol. 41 Issue 4

Edited By: A. Li Wan Po

Impact Factor: 1.833

ISI Journal Citation Reports © Ranking: 2015: 163/253 (Pharmacology & Pharmacy)

Online ISSN: 1365-2710

Recently Published Issues

See all

Free review articles

A systematic review of the prevalence and incidence of prescribing errors with high-risk medicines in hospitals

Bundle interventions used to reduce prescribing and administration errors in hospitalized children: a systematic review

Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck

Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis

Pharmacist-involved care for patients with heart failure and acute coronary syndrome: a systematic review with qualitative and quantitative meta-analysis

Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies

Systematic review of red yeast rice compared with simvastatin in dyslipidaemia

Effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

Quetiapine safety in older adults: a systematic literature review

Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs

Kawasaki disease: a comprehensive review of treatment options

Hyponatraemia induced by terlipressin: a case report and literature review

The role of abuse-deterrent formulations in countering opioid misuse and abuse

Inappropriate prescribing of intravenous fluid in adult inpatients-a literature review of current practice and research

Systematic review of topical amitriptyline for the treatment of neuropathic pain

Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma

Preserving the peritoneal membrane in long-term peritoneal dialysis patients

The role of azithromycin in healthcare-associated pneumonia treatment

Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection

Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions

Heme iron polypeptide for the management of anaemia of chronic kidney disease

Recently Published Articles

  1. Oral antidiabetic drug use and associated health outcomes in cancer patients

    X. Tan, X. Feng, J. Chang, G. Higa, L. Wang and D. Leslie

    Version of Record online: 25 JUL 2016 | DOI: 10.1111/jcpt.12430

    Thumbnail image of graphical abstract

    The relationship between adherence to oral antidiabetic drugs among patients with cancer and healthcare utilization and costs. Adherence was associated with 24% fewer all cause hospitalizations than non-adherence. Moreover, patients with lung cancer had significantly more hospitalizations and ER visits than patients with breast cancer. CCI and DCSI were good predictors of healthcare utilization and costs among our population.

  2. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis

    W. Tan, J. Sun, L. Zhou, Y. Li and X. Wu

    Version of Record online: 21 JUL 2016 | DOI: 10.1111/jcpt.12429

    Thumbnail image of graphical abstract

    Compared to alendronate, zoledronate medications of women with post-menopausal osteoporosis led to 1) better improvements of lumbar spine, femoral neck and total hip bone mineral densities and 2) was associated with superior reductions of the bone resorption marker P1NP and β-CTX expressions.

  3. You have free access to this content
    Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis

    V. L. Ferreira, N. A. Assis Jarek, F. S. Tonin, H. H. L. Borba, A. Wiens and R. Pontarolo

    Version of Record online: 21 JUL 2016 | DOI: 10.1111/jcpt.12426

    Thumbnail image of graphical abstract

    It was carried out network meta-analyses to assess safety of IFN-free therapies for hepatitis C. Two outcomes were evaluated: any adverse events and serious adverse events. Small differences were observed in any adverse events network meta-analysis, but not in serious adverse events network meta-analysis. Here it is presented the consistency analysis based on network meta-analysis results for any adverse events. Significant results are presented as odds ratio with 95% credible interval.

  4. Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review

    S.-H. Hsiao, H.-J. Chang, T.-H. Hsieh, S.-M. Kao, P.-Y. Yeh and T.-J. Wu

    Version of Record online: 19 JUL 2016 | DOI: 10.1111/jcpt.12425

    Characteristics of reported cases of rhabdomyolysis associated with drug interaction between statins and fluconazole.

  5. Cross-reactivity between voriconazole, fluconazole and itraconazole

    D. Benjamin Lash, J. Jolliff, A. Munoz and A. Heidari

    Version of Record online: 19 JUL 2016 | DOI: 10.1111/jcpt.12417

    A 41 year old immunocompetent male with coccidioidomycosis developed fever, eosinophilia, and maculopapular rash from fluconazole. Switching to itraconazole resulted in worsening of the rash and skin sloughing over 25% of his body, while an oral-graded-challenge of voriconazole was tolerated without incident. This is the first report of a lack of cross-reactivity between itraconazole and voriconazole.